Anti-p53 Antibody (Rabbit Monoclonal antibody) General Information
Reacts with: Cynomolgus
Recombinant Cynomolgus p53 / TP53 protein (Catalog#90001-CNAE)
This antibody was obtained from a rabbit immunized with purified, recombinant Cynomolgus p53 / TP53 (Catalog#90001-CNAE; E3U906; Met1-Asp393).
Monoclonal Rabbit IgG Clone #002
0.2 μm filtered solution in PBS
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
Immunofluorescence staining of Cynomolgus p53 in A431 cells. Cells were fixed with 4% PFA, permeabilzed with 0.3% Triton X-100 in PBS, blocked with 10% serum, and incubated with rabbit anti-Cynomolgus p53 monoclonal antibody (1:60) at 37℃ 1 hour. Then cells were stained with the Alexa Fluor® 488-conjugated Goat Anti-rabbit IgG secondary antibody (green). Positive staining was localized to nucleus.
Immunochemical staining of cynomolgus p53 in human lung cancer with rabbit monoclonal antibody (1:200, formalin-fixed paraffin embedded sections).
Immunochemical staining of cynomolgus p53 in human gastric cancer with rabbit monoclonal antibody (1:200, formalin-fixed paraffin embedded sections).
Anti-p53 Antibody: Alternative Names
Anti-p53 Antibody; Anti-TP53 Antibody
p53 Background Information
p53, also known as Tp53, is a DNA-binding protein which belongs to the p53 family. It contains transcription activation, DNA-binding, and oligomerization domains. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 (TP53) is a transcription factor whose protein levels and post-translational modification state alter in response to cellular stress (such as DNA damage, hypoxia, spindle damage). Activation of p53 begins through a number of mechanisms including phosphorylation by ATM, ATR, Chk1 and MAPKs. MDM2 is a ubiquitn ligase that binds p53 and targets p53 for proteasomal degradation. Phosphorylation, p14ARF and USP7 prevent MDM2-p53 interactions, leading to an increase in stable p53 tetramers in the cytoplasm. Further modifications such as methylation and acetylation lead to an increase in Tp53 binding to gene specific response elements. Tp53 regulates a large number of genes (>1 genes) that control a number of key tumor suppressing functions such as cell cycle arrest, DNA repair, senescence and apoptosis. Whilst the activation of p53 often leads to apoptosis, p53 inactivation facilitates tumor progression. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Defects in TP53 are a cause of esophageal cancer, Li-Fraumeni syndrome, lung cancer and adrenocortical carcinoma.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy